


Figure S1. Mean Change of Baseline



A) Omega-3 (EPA + DHA) Index, (B) Omega-6/omega-3 ratio, (C) EPA/ARA ratio, (D) EPA, (E) DHA, and (F) ARA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; PDQ, Perceived Deficits Questionnaire; SDMT-O, Symbol Digit Modalities Test-Oral. Note: * = $P \leq .05$; † = $P \leq .01$; ‡ = $P \leq .001$

Table S1. Baseline Participant Characteristics at 12-Week Primary Study End Point

Characteristics ^a	Swank	Wahls	P value ^b
N	38	39	
Age (y)	46.9 ± 1.7	46.4 ± 1.5	.84
Sex (female)	35 (92.1)	32 (82.1)	.31
MS duration (y)	12.1 ± 1.6	9.3 ± 1.0	.14
DMT use			.83
None	13	10	
Oral	11	11	
Injectable	10	12	
Infused	4	6	
Race (White)	36 (94.7)	38 (97.4)	.99
Education			.32
High school	0 (0.0)	3 (7.7)	
Some college	12 (31.6)	10 (25.6)	
4-year degree	11 (28.9)	8 (20.5)	
Advanced degree	15 (39.5)	18 (46.2)	
Smoking status			.13
Never	29 (76.3)	23 (59.0)	
Former	3 (7.9)	2 (5.1)	
Current	6 (15.8)	14 (35.9)	
Alcohol per month^c			.99
None	6 (15.8)	7 (17.9)	
Within recommendations	29 (76.3)	29 (74.4)	
Above recommendation	3 (7.9)	3 (7.7)	
PDQ total score	32.4 (2.4)	35.9 (2.2)	.28
Attention	71.9 (2.9)	64.8 (3.5)	.12
Retrospective memory	9.15 (0.7)	9.5 (0.6)	.66
Prospective memory	8.00 (0.7)	8.9 (0.6)	.31
Planning	6.2 (0.6)	7.3 (0.6)	.22
SDMT-O	60.4 (1.5)	61.2 (1.5)	.71

DMT, disease-modifying therapy; MS, multiple sclerosis; PDQ, Perceived Deficits Questionnaire; SDMT-O, Symbol Digit Modalities Test-Oral.

^aAll values shown in mean \pm SEM or N (%). Data adapted.⁶

^bSignificance determined by Fisher's exact test or generalized linear models.

^cAlcohol recommendations are less than or equal to 1 standard drink for women and less than or equal to 2 standard drinks for men.

Table S2. Association of 12-Week Serum Fatty Acid Changes with PDQ Subscore Changes

	PDQ attention		PDQ retrospective memory		PDQ prospective memory		PDQ planning memory	
	β-coefficient ^a (95% CI)	P value	β-coefficient (95% CI)	P value	β-coefficient (95% CI)	P value	β-coefficient (95% CI)	P value
Omega-3 (EPA +DHA) index	-2.18 (-7.00, 2.63)	0.37	-0.07 (-5.65, 5.79)	0.98	0.43 (-3.60, 4.47)	0.83	-0.89 (-6.58, 4.81)	0.76
Omega-6/omega-3 ratio	1.71 (-0.81, 4.23)	0.18	0.47 (2.42, 3.46)	0.75	0.21 (-1.87, 2.30)	0.84	0.38 (-2.55, 3.32)	0.80
EPA	-5.60 (-16.1, 4.90)	0.29	3.35 (-8.92, 15.6)	0.59	2.29 (-6.30, 10.9)	0.60	0.54 (-11.8, 12.9)	0.93
DHA	-2.96 (-10.8, 4.91)	0.46	-1.22 (-10.1, 7.70)	0.79	3.21 (-5.19, 7.61)	0.71	-0.95 (-9.88, 7.98)	0.83
EPA/ARA ratio	-54.67 (-133, 23.3)	0.17	-6.74 (-97.0, 83.5)	0.88	-0.00 (-64.8, 64.8)	1	-26.3 (-113, 60.8)	0.55
ARA	-0.38 (-4.47, 3.71)	0.85	-0.36 (-4.2, 4.9)	0.87	0.77 (-2.6, 4.1)	0.65	0.32 (-4.40, 5.05)	0.89

ARA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; PDQ, Perceived Deficits Questionnaire.

^aThe β-coefficient is the degree of change in the outcome variable for every 1 unit of change in the independent variable. The *t* test assesses whether the beta coefficient is statistically and significantly different from zero.

Table S3. Mediation Effect of 12-Week Serum Fatty Acid Changes on PDQ Subscores

	PDQ attention		PDQ retrospective memory		PDQ prospective memory		PDQ planning memory	
	Percent mediated (95% CI)	P value						
Omega-3 (EPA + DHA) index	11.9 (-33.9, 57.6)	0.61	5.35 (-45.3, 56.0)	0.84	-0.04 (-55.4, 55.3)	0.99	-1.35 (-49.8, 47.1)	0.96
Omega-6/omega-3 ratio	38.5 (-30.9, 108)	0.28	22.6 (-56.5, 101.7)	0.58	18.5 (-66.3, 103.3)	0.67	9.59 (-61.8, 81.0)	0.79
EPA	6.99 (-25.4, 39.4)	0.67	2.36 (-35.7, 40.4)	0.90	-4.53 (-45.7, 36.6)	0.83	1.87 (-33.03, 36.8)	0.92
DHA	17.3 (-32.7, 67.2)	0.50	22.4 (-37.3, 82.2)	0.46	3.62 (-58.6, 65.8)	0.91	-2.14 (-55.1, 50.8)	0.94
EPA/ARA ratio	15.6 (-13.4, 44.6)	0.29	15.8 (-16.2, 47.9)	0.33	8.68 (-28.8, 46.2)	0.65	12.50 (-18.5, 43.5)	0.43
ARA	-0.34 (-4.42, 3.74)	0.87	-0.47 (-6.08, 5.13)	0.87	-0.37 (-4.85, 4.11)	0.87	-3.39 (-5.08, 4.30)	0.87

ARA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; PDQ, Perceived Deficits Questionnaire.